SNY - Sanofi

NasdaqGS - NasdaqGS Real-time price. Currency in USD
41.95
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close41.95
Open41.75
Bid41.92 x 3200
Ask41.93 x 900
Day's range41.64 - 42.00
52-week range40.19 - 45.62
Volume3,352,263
Avg. volume1,533,376
Market cap103.835B
Beta (3Y monthly)0.45
PE ratio (TTM)21.62
EPS (TTM)1.94
Earnings dateN/A
Forward dividend & yield1.74 (4.18%)
Ex-dividend date2019-05-07
1y target est52.67
Trade prices are not sourced from all markets
  • How Does Sanofi (EPA:SAN) Fare As A Dividend Stock?
    Simply Wall St.2 days ago

    How Does Sanofi (EPA:SAN) Fare As A Dividend Stock?

    Today we'll take a closer look at Sanofi (EPA:SAN) from a dividend investor's perspective. Owning a strong business...

  • New Strong Buy Stocks for July 18th
    Zacks3 days ago

    New Strong Buy Stocks for July 18th

    New Strong Buy Stocks for July 18th

  • Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs
    Zacks4 days ago

    Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs

    Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its workforce by 28% and annual burn rate by 25%. Shares fall in after-hours trading.

  • Merck's Antibiotic Recarbrio Gets FDA Nod for Infections
    Zacks4 days ago

    Merck's Antibiotic Recarbrio Gets FDA Nod for Infections

    The FDA approves Merck's (MRK) anti-bacterial injection, MK-7655A, to be marketed as Recarbrio.

  • AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes
    Zacks6 days ago

    AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes

    AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.

  • AI Drug Hunters Could Give Big Pharma a Run for Its Money
    Bloomberg6 days ago

    AI Drug Hunters Could Give Big Pharma a Run for Its Money

    (Bloomberg) -- Machine-learning technology has beaten humans at games of chess and Go to worldwide fanfare. A demonstration of its eerily lifelike prowess in making phone calls to unsuspecting people went viral.But a less-noticed win for DeepMind, the artificial-intelligence arm of Google’s parent Alphabet Inc., at a biennial biology conference could upend how drugmakers find and develop new medicines. It could also dial up pressure on the world’s largest pharmaceutical companies to prepare for a technological arms race. Already, a new breed of upstarts are jumping into the fray.In December, at the CASP13 meeting in Riviera Maya, Mexico, DeepMind beat seasoned biologists at predicting the shapes of proteins, the basic building blocks of disease. The seemingly esoteric pursuit has serious implications: A tool that can accurately model protein structures could speed up the development of new drugs. “Absolutely stunning,” tweeted one scientist after the raw results were posted online. “It was a total surprise,” said conference founder John Moult, a University of Maryland computational biologist. “Compared to the history of what we had been able to do, it was pretty spectacular.” Sorting out the structure of proteins in order to find ways for medicines to attack disease is an enormously complex problem. Researchers still don’t fully understand the rules for how proteins are built. And then there’s the math: There are more possible protein shapes than there are atoms in the universe, making prediction a herculean undertaking of computation. For a quarter century, computational biologists have labored to devise software equal to the task.Enter DeepMind. With limited experience in protein folding — the physical process by which a protein acquires its three-dimensional shape — but armed with the latest neural-network algorithms, DeepMind did more than what 50 top labs from around the world could accomplish. Excitement rippled around the Mayan-themed resort where the meeting was held. Two DeepMind presenters were peppered with questions from scientists about how they had done it. Within hours, the British newspaper The Guardian said DeepMind’s AI could “usher in new era of medical progress.”  In a blog post, the company bragged that its protein models were “far more accurate than any that have come before,” opening up “new potential within drug discovery.”In an email, DeepMind said its scientists were “fully focused on their research” and not available for interviews. DeepMind’s simulation doesn’t yet produce the kind of atomic-level resolution that is important for drug discovery. And though many companies are looking for ways to use computers to identify new medications, few machine-learning-based drugs have progressed to the point of being tested in humans. It will be years before anyone knows whether such software can regularly spot promising therapies that researchers might otherwise have missed.Artificial intelligence is a chic catchphrase in health care, often trotted out as a cure-all for whatever ails the industry. It has been held up as a potential solution to fix cumbersome electronic medical records, speed up diagnosis and make surgery more precise. DeepMind’s victory points to a possible practical application for the technology in one of the most expensive and failure-prone parts of the pharmaceutical business. Some observers said that the fact that a team of outsiders could make such significant progress in untangling one of the most vexing problems of biology is a black eye for researchers in the field. It could also be a portent for the drug industry, which spends billions on research and development, but was beaten to the punch.  Mohammed AlQuraishi, a Harvard computational biology researcher who attended the conference, wrote in a blog post that giant pharmaceutical companies haven’t put a serious effort into protein folding, essentially ceding the ground to tech companies. While drug companies dithered, “Alphabet swoops in and sets up camp right in their backyard,” he wrote.Finding new drugs and bringing them to market is notoriously difficult. According to some estimates, big drugmakers spend more than $2.5 billion to get a new medicine to patients. Just one of every 10 therapies that enters human clinical trials makes it to the pharmacy. And science moves slowly: In the nearly 20 years since the human genome was sequenced, researchers have found treatments for a tiny fraction of the approximately 7,000 known rare diseases.Further, there are approximately 20,000 genes that can malfunction in at least 100,000 ways, and millions of possible interactions between the resultant proteins. It’s impossible for drug hunters to probe all of those combinations by hand.“If we want to understand the other 97 percent of human biology, we will have to acknowledge it is too complex for humans,” said Chris Gibson, the co-founder and Chief Executive Officer of Recursion Pharmaceuticals, a Salt Lake City-based startup that uses machine learning to hunt for new therapies.Companies like Recursion are rapidly luring investors. Venture capitalists poured $1.08 billion into AI and machine-learning startups focused on drug discovery last year, according to data provider PitchBook, up from just $237 million in 2016, and have already put in $699 million more so far this year.  Recursion raised $121 million in its latest financing round, the company said on Monday, from investors including Intermountain Ventures and the Regents of the University of Minnesota. It has a valuation of $646 million, according to PitchBook. “It is a very ambitious company. They are thinking in terms of radically changing the industry,” said Marina Record, an investment manager at Baillie Gifford & Co. in Scotland, which led the funding round.Established drugmakers are racing to ally with companies doing similar work.In April, Gilead Sciences Inc. agreed to a deal with Insitro, a startup led by the former Stanford University machine-learning expert Daphne Koller, to find ways to treat liver disease NASH. AstraZeneca Plc the same month linked up with U.K.-based BenevolentAI to identify treatments for kidney disease and lung fibrosis. In June, GlaxoSmithKline Plc partnered with gene-editing pioneers at the University of California in a $67 million target-hunting collaboration that will use AI.“Where else would you accept a 1-in-10 success rate?” said GlaxoSmithKline senior vice president Tony Wood, who heads medicinal science and technology for the British pharmaceutical giant. “If we could double that to 20% it would be phenomenal.”  Machine-learning methods “are going to be critical” to drug discovery, said Juan Alvarez, an associate vice president for computational chemistry at Merck & Co. The giant drugmaker is developing AI tools to help its chemists accelerate the laborious process of crafting chemicals to block aberrant proteins. Early machine-learning efforts have already contributed to drugs in human testing, while the first drugs based on more advanced neural-network methods could hit trials in several years, Alvarez said.Artificial intelligence could be used to scan millions of high-resolution cellular images—more than humans could ever process on their own—to identify therapies that could make diseased cells healthier in unexpected ways.At Recursion, one of the earliest startups to use such methods, each week robots apply thousands of potential drugs to various types of diseased cells, in 400,000 to 500,000 miniature experiments that generate 5 to 10 million cellular images. Machine-learning algorithms then scan the images, searching for compounds that disrupt disease without harming healthy cells.  The initial algorithms were coded by hand to interpret basic cellular features, but Recursion is increasingly using neural-network methods that directly interpret the images and may spot patterns human programmers wouldn't have looked for. Computer scientists work in tandem with biologists in the laboratory to refine the leads.  The company, which has agreed to rare-disease deals with Takeda Pharmaceutical Co. Ltd. and Sanofi, generated more than 2.5 petabytes of data in the past few years, a total that exceeds roughly the bandwidth of all Hollywood feature films. What the company is doing “just wasn't feasible six, or seven, or eight years ago,” said Gibson, its founder. Gibson first turned to machine learning as a graduate student at the University of Utah searching for treatments for cerebral cavernous malformation, which causes abnormal clumps of leaky blood vessels in the brain. The disorder affects about 1 in 500 people, according to the Angioma Alliance, and while often silent, can lead to seizures, speech or vision difficulties, and devastating brain hemorrhages. About a quarter of patients have a genetic form of the illness that is more likely to cause multiple malformations. Even though the three genes that cause it are known, there are no pharmaceutical treatments. One drug Gibson tested at the University of Utah based on the prevailing understanding of the disease made its symptoms worse in animals.Frustrated, Gibson and his colleagues used open-source machine-learning software for scanning cellular images to probe the effects of 2,100 compounds, searching for ones that improved the appearance and function of blood vessel cells that carried the bad genes. The algorithms pointed to an unexpected chemical that reduced leaky blood vessels in animal tests by 50 percent. That drug, set to enter second-stage human trials next year, led to the founding of Recursion.Other parts of Alphabet, as well as the AI research unit of social-media giant Facebook Inc., which quietly released a paper using deep learning to analyze 250 million protein sequences in April, are creeping into pharmaceutical-company turf. This spring, AI researchers at Google unveiled a neural network that can predict the function of a protein from its sequence of amino acids, which can help biologists understand what a newly discovered protein does. AI proponents say that nobody is talking about taking human researchers out of the equation. The goal is “augmenting and enhancing the decision-making capacity of scientists,” said Jackie Hunter, a former GlaxoSmithKline research executive who now leads clinical programs at BenevolentAI. In the short run, it’s more likely that AI-based simulations will be used to game out whether prospective drugs will be effective before going to a full-on clinical trial.An aerospace company “won’t build and fly a plane without building it on the computer first and simulating it under many conditions,” said Colin Hill of GNS Healthcare, a startup using AI to model disease, whose investors include Amgen Inc. In the future, drugmakers won’t begin clinical trials without a virtual dry run, Hill said.Still, the surprise that unfolded in Mexico has increased the tempo. DeepMind “basically beat everyone by a sizeable margin” said AlQuraishi, the Harvard researcher.  If drugmakers don’t take the threat seriously, he said, they could be left in the dust.  To contact the author of this story: Robert Langreth in New York at rlangreth@bloomberg.netTo contact the editor responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Aimmune Down on Negative ICER Review on Allergy Candidate
    Zacks9 days ago

    Aimmune Down on Negative ICER Review on Allergy Candidate

    Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.

  • SNY or PFE: Which Is the Better Value Stock Right Now?
    Zacks9 days ago

    SNY or PFE: Which Is the Better Value Stock Right Now?

    SNY vs. PFE: Which Stock Is the Better Value Option?

  • Are Investors Undervaluing Sanofi (SNY) Right Now?
    Zacks9 days ago

    Are Investors Undervaluing Sanofi (SNY) Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
    Zacks9 days ago

    Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY

    Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.

  • FDA Accepts Sanofi's BLA for Myeloma Candidate to Review
    Zacks10 days ago

    FDA Accepts Sanofi's BLA for Myeloma Candidate to Review

    The FDA accepts for review Sanofi's (SNY) BLA for isatuximab as a potential treatment for relapsed/refractory multiple myeloma. The FDA will declare its decision by April 2020.

  • Court Ruling Topples Trump Order, No Price Display in TV Ads
    Zacks11 days ago

    Court Ruling Topples Trump Order, No Price Display in TV Ads

    The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

  • Reuters - UK Focus12 days ago

    UPDATE 3-WHO keeps key lung cancer drugs off its essential medicines list

    GENEVA/ZURICH, July 9 (Reuters) - The world's master list of recommended medicines got an update on Tuesday when the World Health Organization (WHO) published a biennial revision, adding 28 drugs including an abortion pill but leaving out several breakthrough treatments for lung cancer. The WHO's Essential Medicines List, which includes treatments that the WHO regards as global standards that should be available everywhere, aims to help governments make the best choices for their health systems. The latest edition rejected Keytruda from Merck, Opdivo from Bristol-Myers Squibb and Tecentriq from Roche for non-small cell lung cancer, where they have combined for billions of dollars in sales in recent years.

  • Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs
    Zacks16 days ago

    Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs

    Pfizer (PFE) provides several regulatory/pipeline updates. CHMP gives nod to several drugs.

  • Glaxo's Dovato Wins EU Nod, RA Candidate Enters Phase III
    Zacks17 days ago

    Glaxo's Dovato Wins EU Nod, RA Candidate Enters Phase III

    Glaxo (GSK) gets an EU approval for Dovato, its single-tablet two-drug HIV regimen. It commences phase III studies on its anti GM-CSF antibody, otilimab, for patients with rheumatoid arthritis.

  • Bloomberg18 days ago

    Euro-Area's Biggest Companies Index Enters Bull Market on Trade

    (Bloomberg) -- The gauge for the euro-area’s largest listed companies closed in a bull market on Wednesday, extending a rally fueled by the trade truce between the U.S. and China as well as by bets on softer monetary policy.The Euro Stoxx 50 Index gained 0.9% by the close, up about 20% from a late-December low. Equities in the region, led by the tech sector, are getting a boost from the decision by the U.S. and China to resume trade talks. Utilities stocks have also rallied recently amid falling bond yields.An added boost to sentiment is softer rhetoric from global central banks, which last month signaled openness to rate cuts and further stimulus. In the past 24 hours, Christine Lagarde was nominated to take the helm of the European Central Bank later this year, ushering in a candidate whom analysts anticipate will take up departing President Mario Draghi’s mantle in providing stimulus.“The key driving force behind the recent rally has been the unexpected decision by Draghi to announce much greater central bank support than many investors had expected,” said Andrew Milligan, head of global strategy at Aberdeen Standard Investments in Edinburgh. “Looking ahead, we need to see market expectations of easier central bank policy matched by continued good news from the politicians on trade -- or investor sentiment will turn again.”Aberdeen is overweight global equities, but neutral on European stocks because of political risk premia.Some of Wednesday’s biggest advancers included Anheuser-Busch InBev NV, which rose 4.1% after a sale of shares in its Asia Pacific beer unit was priced at the high end of the range. Sanofi added 1.5% after Biocorp said it’s in exclusive talks about introducing its Mallya connected device into the company’s integrated diabetes care platform.“While the European economy remains slow growing with the important manufacturing sector still suffering from a modest recession as global trade stagnates, there are many multinational companies in Europe with solid global operations,” Milligan said.To contact the reporter on this story: Ksenia Galouchko in London at kgalouchko1@bloomberg.netTo contact the editors responsible for this story: Blaise Robinson at brobinson58@bloomberg.net, Paul Jarvis, Jon MenonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Amarin (AMRN) Issues Update on Q2 Sales, Raises '19 Guidance
    Zacks18 days ago

    Amarin (AMRN) Issues Update on Q2 Sales, Raises '19 Guidance

    Amarin announces strong preliminary sales of Vascepa in the second quarter. The company increases sales guidance for 2019.

  • Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis
    Zacks19 days ago

    Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis

    Pfizer's (PFE) Eucrisa ointment is found safe in a late-stage label expansion study for treating mild to moderate atopic dermatitis in minors aged 3 months to 2 years.

  • Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer
    Zacks19 days ago

    Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer

    Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.

  • Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation
    Zacks20 days ago

    Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation

    Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.

  • Novavax (NVAX) Seeks Accelerated Approval Pathway for NanoFlu
    Zacks23 days ago

    Novavax (NVAX) Seeks Accelerated Approval Pathway for NanoFlu

    Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.

  • FDA Accepts Sanofi's BLA for Meningitis Vaccine to Review
    Zacks24 days ago

    FDA Accepts Sanofi's BLA for Meningitis Vaccine to Review

    The FDA accepts for review Sanofi's (SNY) BLA for MenQuadfi, a meningococcal vaccine candidate, presently under development to prevent meningococcal meningitis.

  • Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion
    Zacks24 days ago

    Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion

    Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.

  • This would be the worst-case scenario for health stocks, according to UBS
    MarketWatch29 days ago

    This would be the worst-case scenario for health stocks, according to UBS

    Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.

  • Sanofi/Regeneron's Asthma Candidate Meets Goal in Study
    Zackslast month

    Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

    Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes